GRI Bio Stock Soars 56% on Positive IPF Phase 2a Results and Funding Boost

Introduction

GRI Bio Inc (NASDAQ: GRI) is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The firm develops therapies that target natural killer T (NKT) cells to modulate early steps in the inflammatory cascade underlying autoimmune, fibrotic, and inflammatory diseases. As of September 11, 2025, GRI shares closed at $2.4399, reflecting a 56.40% increase on a volume of 2,207,949.

Corporate Structure

Founded in May 2009 by Vipin Kumar Chaturvedi, GRI Bio operates with a small team of 2–10 employees. The company maintains a library of over 500 proprietary compounds to support its research pipeline. GRI Bio’s common stock trades on the Nasdaq Capital Market under the ticker “GRI.”

Biopharmaceuticals by little plant

Developments and News

• August 14, 2025: Filed Form 10-Q for the quarter ended June 30, 2025, disclosing operations and liquidity.
• August 15, 2025: Filed a prospectus supplement (Rule 424(b)(3)) offering 202,000 shares of common stock, 1,186,888 pre-funded warrants, and Series E warrants exercisable for 5,450,774 shares in total. The last reported sale price on August 11 was $1.165 per share.
• August 20, 2025: Submitted Form 8-K reporting material events under Items 7.01 and 9.01.
• August 19–21, 2025: Participated in the 9th Annual IPF Summit in Boston, providing presentations on GRI-0621 for idiopathic pulmonary fibrosis (IPF).
• August 20, 2025: Announced interim six-week lung function results from the Phase 2a study of GRI-0621 in IPF, indicating no decline in forced vital capacity (FVC) relative to baseline.
• September 9, 2025: Marc Hertz, Chief Executive Officer, presented at the H.C. Wainwright 27th Annual Global Investment Conference in New York City.

Financial and Strategic Aspects

As of Q2 2025, GRI Bio reported:

• Market capitalization of approximately $3.6 million
• Total cash and cash equivalents of $5.12 million
• Trailing twelve-month net loss of $11.92 million
• Debt-to-equity ratio of 2.89%
• Trailing P/E of 0.02 and EPS (TTM) of 90.80 (reflecting negative net income)

Strategically, GRI Bio’s lead program, GRI-0621, is an oral iNKT cell inhibitor for IPF. Additionally, the company is developing a pipeline of type 2 diverse NKT (dNKT) agonists for the treatment of systemic lupus erythematosus. The firm's continuous equity and warrant offerings under Rule 415 aim to support ongoing clinical development and expand its research capabilities.

Market Position and Industry Context

Operating as a micro-cap company in the Biotechnology sector, GRI Bio’s share price has ranged between $1.10 and $30.43 over the past 52 weeks. Trading volatility is indicated by a beta near –1.8. The company competes in the inflammatory and autoimmune therapeutic areas, with a focus on NKT cell regulation at early stages of the inflammatory cascade. GRI Bio’s market cap under $5 million places it among small-cap public peers, and its cash runway is influenced by successful capital raising and achievement of clinical milestones.

tl;dr

On September 11, 2025, GRI Bio’s stock increased by 56.40% to $2.4399 following interest generated by the August 20 Phase 2a data indicating stable FVC at six weeks for IPF patients. The company conducted equity and warrant offerings in mid-August and reported a cash balance of $5.12 million as of June 30, 2025. CEO presentations at the September 9 H.C. Wainwright conference and ongoing development of the lupus program are expected to be significant factors in the company's activities for the remainder of 2025.